619 related articles for article (PubMed ID: 17409312)
1. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
4. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
[TBL] [Abstract][Full Text] [Related]
6. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
7. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
9. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
11. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
[TBL] [Abstract][Full Text] [Related]
16. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H; Jackson LL; Warnock DG
J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
[TBL] [Abstract][Full Text] [Related]
19. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
20. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.
Schiffmann R; Martin RA; Reimschisel T; Johnson K; Castaneda V; Lien YH; Pastores GM; Kampmann C; Ries M; Clarke JT
J Pediatr; 2010 May; 156(5):832-7, 837.e1. PubMed ID: 20097359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]